RAJEEV SHARMA: Open Payments
NPI 1710309950 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,132 in 50 payments from 11 companies in 2025. Trend: 2023 $944 · 2024 $1,056 · 2025 $1,132
Food & beverage: $1,032Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $239 |
| Janssen Pharmaceuticals, Inc | 6 | $184 |
| Otsuka America Pharmaceutical, Inc. | 5 | $123 |
| Teva Pharmaceuticals USA, Inc. | 2 | $122 |
| Neurocrine BioSciences, Inc. | 4 | $107 |
| Lundbeck LLC | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $52 |
Products named: VRAYLAR, INVEGA SUSTENNA, ABILIFY ASIMTUFII, INGREZZA, Auvelity, CAPLYTA, COBENFY, ARISTADA.
Industry payments across MA — which companies pay providers there.
